Cancer Immunotherapy Market By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy, Cytokine-based Immunotherapy, Oncolytic Virus Therapy, Others), By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Others), By Route of Administration (Intravenous, Oral, Intratumoral, Subcutaneous, Others), By Biomarker Type (PD-L1 Expression, Microsatellite Instability, Tumor Mutational Burden, BRCA Mutation, HER2 Expression, Others), and By End User (Hospitals, Cancer Research Centers, Specialty Clinics, Ambulatory Surgical Centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cancer Immunotherapy Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. How does biotechnology advancement contribute to cancer immunotherapy growth?

3.2.2. Can rising prevalence of cancer boost immunotherapy market expansion?

3.2.3. Will enhanced clinical trials lead to more effective treatments?

3.3. Key industry pitfalls & challenges

3.3.1. Does high cost of immunotherapy limit patient accessibility globally?

3.3.2. Are there regulatory challenges slowing down market product approvals?

3.3.3. Could limited awareness among patients hinder immunotherapy adoption?

3.4. Market Opportunities

3.4.1. Will emerging nanotechnology enhance delivery mechanisms in treatments?

3.4.2. Can rising investment in R&D lead to market breakthroughs?

3.4.3. Is personalization of therapies creating new market expansion paths?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cancer Immunotherapy Market, Therapy Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Monoclonal Antibodies

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Immune Checkpoint Inhibitors

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Cancer Vaccines

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Adoptive Cell Therapy

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Cytokine-based Immunotherapy

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Oncolytic Virus Therapy

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.8. Others

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Cancer Immunotherapy Market, Cancer Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Lung Cancer

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Breast Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Prostate Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Colorectal Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Melanoma

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Blood Cancers

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Cancer Immunotherapy Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Intravenous

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Oral

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Intratumoral

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Subcutaneous

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Others

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Cancer Immunotherapy Market, Biomarker Type Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Biomarker Type, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. PD-L1 Expression

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Microsatellite Instability

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Tumor Mutational Burden

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. BRCA Mutation

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. HER2 Expression

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.7. Others

7.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Cancer Immunotherapy Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Cancer Research Centers

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Specialty Clinics

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Ambulatory Surgical Centers

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.6. Others

8.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Cancer Immunotherapy Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Therapy Type, 2025-2035

9.2.3. North America Market Revenue, By Cancer Type, 2025-2035

9.2.4. North America Market Revenue, By Route of Administration, 2025-2035

9.2.5. North America Market Revenue, By Biomarker Type, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Therapy Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Cancer Type, 2025-2035

9.2.7.3. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.4. U.S. Market Revenue, By Biomarker Type, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Therapy Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Cancer Type, 2025-2035

9.2.8.3. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.4. Canada Market Revenue, By Biomarker Type, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Therapy Type, 2025-2035

9.3.3. Europe Market Revenue, By Cancer Type, 2025-2035

9.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.5. Europe Market Revenue, By Biomarker Type, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Therapy Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Cancer Type, 2025-2035

9.3.7.3. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.4. Germany Market Revenue, By Biomarker Type, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Therapy Type, 2025-2035

9.3.8.2. France Market Revenue, By Cancer Type, 2025-2035

9.3.8.3. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.4. France Market Revenue, By Biomarker Type, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Therapy Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Cancer Type, 2025-2035

9.3.9.3. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.4. U.K. Market Revenue, By Biomarker Type, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Therapy Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Cancer Type, 2025-2035

9.3.10.3. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.4. Italy Market Revenue, By Biomarker Type, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Therapy Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Cancer Type, 2025-2035

9.3.11.3. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.4. Spain Market Revenue, By Biomarker Type, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Biomarker Type, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Biomarker Type, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Therapy Type, 2025-2035

9.4.7.2. China Market Revenue, By Cancer Type, 2025-2035

9.4.7.3. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.4. China Market Revenue, By Biomarker Type, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Therapy Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Cancer Type, 2025-2035

9.4.8.3. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.4. Japan Market Revenue, By Biomarker Type, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Therapy Type, 2025-2035

9.4.9.2. India Market Revenue, By Cancer Type, 2025-2035

9.4.9.3. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.4. India Market Revenue, By Biomarker Type, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Therapy Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Cancer Type, 2025-2035

9.4.10.3. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.4. Australia Market Revenue, By Biomarker Type, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Therapy Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Cancer Type, 2025-2035

9.4.11.3. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.4. South Korea Market Revenue, By Biomarker Type, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Therapy Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Cancer Type, 2025-2035

9.4.12.3. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.4. Singapore Market Revenue, By Biomarker Type, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Biomarker Type, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.3. Latin America Market Revenue, By Cancer Type, 2025-2035

9.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.5. Latin America Market Revenue, By Biomarker Type, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Therapy Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Cancer Type, 2025-2035

9.5.7.3. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.4. Brazil Market Revenue, By Biomarker Type, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Therapy Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Cancer Type, 2025-2035

9.5.8.3. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.4. Argentina Market Revenue, By Biomarker Type, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Therapy Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Cancer Type, 2025-2035

9.5.9.3. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.4. Mexico Market Revenue, By Biomarker Type, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Cancer Type, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Biomarker Type, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Therapy Type, 2025-2035

9.6.3. MEA Market Revenue, By Cancer Type, 2025-2035

9.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.5. MEA Market Revenue, By Biomarker Type, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Therapy Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Cancer Type, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Biomarker Type, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Therapy Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Cancer Type, 2025-2035

9.6.8.3. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.4. South Africa Market Revenue, By Biomarker Type, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Biomarker Type, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Bristol-Myers Squibb

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Roche Holding AG

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. AstraZeneca plc

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Novartis AG

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Pfizer Inc.

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Amgen Inc.

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Johnson & Johnson

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Regeneron Pharmaceuticals, Inc.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Gilead Sciences, Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Moderna, Inc.

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Bluebird Bio, Inc.

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Seagen Inc.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. CureVac AG

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Adaptimmune Therapeutics plc

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis